Both of them were previously working for Mallinckrodt pharmaceuticals
BioTime has announced its new board of directors, Mr Michael H Mulroy and Mr Stephen L Cartt. Mr Mulroy has been appointed to the board to fill a vacancy and Mr Cartt has been nominated for election to the Board at the Company's upcoming annual shareholders' meeting.
Mr Mulroy recently served as executive vice president, strategic affairs and general counsel of the autoimmune and rare diseases business unit, Mallinckrodt Pharmaceuticals. Mr Cartt has served as chief operating officer of the autoimmune and rare diseases business unit of Mallinckrodt.
"We are very pleased that Mr Mike Mulroy and Mr Steve Cartt are joining our Board of Directors. Both of these executives have exceptional track records of creating substantial shareholder value over time. As BioTime and its subsidiaries move into clinical trials with several products, we are focused on adding biopharmaceutical industry executives to our management teams and boards of directors who have records of successfully advancing products through clinical trials and commercialisation while creating substantial shareholder value," commented Mr Michael D West, CEO, BioTime.
"We look forward to working closely with both of them to build significant value for BioTime's shareholders over time," he added.
